[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578677":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":40,"responsibleParty":57,"collaborators":26,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":26,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":43,"whyStopped":26,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"hospitalized","ACTIVE_COMPARATOR","Hospedalized patients",[13],"Other: Hospital patient management",{"label":15,"type":16,"description":17,"interventionNames":18},"early discarged","EXPERIMENTAL","Early discarged patients",[19],"Procedure: Home patient management",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Home patient management","with support therapy, Granulocyte growth factor, blood transfusion",[15],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Hospital patient management","all procedures and exams needed",[9],[32],{"name":33,"affiliation":5,"role":34},"Pier Luigi Zinzani, MD","PRINCIPAL_INVESTIGATOR",[36],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},"CONTACT","+39 0512143680","pierluigi.zinzani@unibo.it",[41],{"facility":42,"status":43,"city":44,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"IRCCS-AOU di Bologna","RECRUITING","Bologna","40138","Italy","IT",{"type":49,"coordinates":50},"Point",[51,52],11.33875,44.49381,{"lat":52,"lon":51},[55,56],{"name":33,"role":37,"phone":38,"phoneExt":26,"email":39},{"name":33,"role":34,"phone":26,"phoneExt":26,"email":26},{"type":58,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100578677","safety-and-feasibility-of-a-multidisciplinary-programme-of-integrated-hospital-home-management-with-early-discharge-of-patients-with-haematological-malignancies-undergoing-high-dose-chemotherapy-in-hospital-100578677",false,"NCT06814405","Safety and Feasibility of a Multidisciplinary Programme of Integrated Hospital-home Management With Early Discharge of Patients With Haematological Malignancies Undergoing High-dose Chemotherapy in Hospital","AMICO","Inclusion Criteria:\n\n* Diagnosis of haematological malignancy undergoing high-dose chemotherapy (sub- or myeloablative)\n* Age between 18-75 years\n* WHO Performance Status \\\u003C 2 or Karnofsky ≥ 60%\n* Adequate organ function:\n* FE≥ 50% and absence of significant electrocardiographic changes\n* eVFG \\> 40 ml\u002Fmin and\u002For creatinine ≤ 1.6 mg\u002Fdl (CPK-EPI formula)\n* total bilirubin ≤ 3 mg\u002Fml\n* AST\u002FALT ≤ 5 ULN\n* SpO2 ≥ 94%\n* Reinfusion ≥ 2x106 CD34+\u002FKg\n* Presence of a 24-hour SARS-COV-2 vaccinated caregiver\n* Home \\\u003C 45 minutes' drive from hospital\n* Informed consent obtained\n\nExclusion Criteria:\n\n* Diagnosis of haematological malignancy at onset or in progression\n* Significant cardiovascular disease: heart failure NYHA class 3 or 4, uncontrolled angina, history of myocardial infarction, unstable angina or stroke in the previous 6 months, uncontrolled hypertension, significant arrhythmias not controlled by medication","ALL","18 Years","75 Years",{"count":70,"type":71},100,"ESTIMATED","INTERVENTIONAL",[74],"NA","Patients undergoing particular intensive and (sub)myeloablative chemotherapy regimens with subsequent autologous stem cell transplant currently have a relatively low rate of therapy-related complications, both infectious and non-infectious (organ damage), and can therefore benefit from a specific multidisciplinary care programme at home. In this clinical context, early discharge and domicile of the patient after therapy provided in a hospital setting may represent a procedure designed to better intercept the patient's personal needs. In addition, it may make it possible to increase the limited availability of beds in the face of the progressive increase in demand, allowing the provision of hospital therapies to a higher number of patients with a consequent reduction in pre-hospital waiting times.",[77],"Haematological Malignancy",[79,80,81,82],"hospitalisation","early discharge","domiciliation","supportive therapy","2025-02-03",{"date":85,"type":86},"2025-02-07","ACTUAL",{"date":88,"type":86},"2023-05-11",{"date":90,"type":71},"2025-12-31",{"name":5,"class":6},1]